top of page

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

COLVILLE, WA

58°F

Chance Light Rain

About
Contact
Place an Ad
Submissions
Freelance Opportunities
Join Our Team

LETTERS TO THE EDITOR

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.09 -0.34 (-0.83%)

Delayed Quote Updated: 3:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >

UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup ↗

September 05, 2026

Via Chartmill

UroGen (URGN) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.

Via The Motley Fool

Topics Earnings Intellectual Property

Urogen Pharma Q2 Earnings Call Highlights ↗

August 05, 2026

Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain...

Via MarketBeat

Topics Earnings

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗

July 12, 2026

Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with 119,763 shares worth $4.82 million.

Via The Motley Fool

Topics Regulatory Compliance

Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗

July 09, 2026

Via Chartmill

UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗

June 08, 2026

Via Chartmill

UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗

May 06, 2026

Via Chartmill

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗

June 30, 2026

Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗

June 14, 2026

Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗

March 02, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Via The Motley Fool

UroGen (URGN) Q1 2026 Earnings Transcript ↗

May 07, 2026

UroGen (URGN) Q1 2026 Earnings Transcript

Via The Motley Fool

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

Via The Motley Fool

Topics Regulatory Compliance

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

Via The Motley Fool

Topics Regulatory Compliance

UroGen (URGN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

UroGen (URGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

Via The Motley Fool

Topics Death Regulatory Compliance

UroGen (URGN) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

UroGen (URGN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗

November 06, 2025

UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 24, 2025

Via Benzinga

UroGen (URGN) Q2 Revenue Rises 11% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat ↗

August 07, 2025

UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped...

Via Chartmill

3 Bullish Biotech Stocks With Explosive Growth Trends ↗

July 21, 2025

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

Via MarketBeat

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday ↗

June 16, 2025

Via Benzinga

US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert ↗

June 16, 2025

U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Local News
Government
Business
Sports
Arts & Entertainment
Farm & Ranch
Great Outdoors
Profiles

Out of the Past
Letters to the Editor
Classifieds
Announcements
Events Calendar
Obituaries
Commissioner Agendas
Superior Court Dockets

Home

About

Contact

Advertising

Legal Notices

Terms of Use

Privacy Policy

Accessibility

Submissions

Place an Ad

Submit an Event

News Tips

Corrections

Letters to the Editor

Freelance Opportunities

Home Delivery

Join our Team

Statesman-Examiner

220 S. Main St.
Colville, WA 99114

Hours: Mon.-Fri., 8 a.m.-5 p.m.

509-684-4567
editor@statesmanexaminer.com

PHOTO GALLERY

Website Designed by Amber S. King – Creative Design

Home
About
Contact
Submissions

About
Contact
Place an Ad
Submissions
Freelance Opportunities
Join Our Team

bottom of page